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SUMMARY. The combination treatment of peginterferon
alpha-2a (PEG-IFN alpha-2a; Pegasys
 ) plus ribavirin (RBV)
is recommended as a standard care for HCV infections. Side
effects and aspects of efﬁcacy and safety have to be balanced.
This study evaluates clinical practice data on safety and
efﬁcacy of HCV treatment with PEG-IFN in combination with
RBV over 24 and 48 weeks. This study was a phase III,
multi-centre, open-label study with two treatment groups:
PEG-IFN in combination with RBV for 24 or 48 weeks. The
allocation to the treatment groups was at the discretion of
the investigator; 309 patients entered active treatment: 90
patients received PEG-IFN plus RBV for 24 weeks and 219
patients PEG-IFN plus RBV for 48 weeks. A sustained viro-
logical response (SVR) was achieved in 48.9% of all patients.
Genotype 1 patients with a 48-week combination treatment
achieved an SVR of 39.9%. In the 48-week group a low
baseline viral load was associated with a higher SVR rate
(47.0% vs. 32.4%). For genotype 2 or 3 patients, the SVR
was 67.9%. For these patients there was no relevant differ-
ence between patients with low and high viral loads; 97.7%
of the patients experienced at least one adverse event. The
incidence of serious adverse events was distinctly lower in
the 24-week group (4.4% vs. 10.5%). This investigation
conﬁrms the well-known risk–beneﬁt ratio found in con-
trolled studies in a clinical practice setting. The safety proﬁle
is similar and shows the highest incidence of adverse events
in the ﬁrst 12 weeks of treatment.
Keywords: hepatitis C, pegylated interferon, polymerase
chain reaction, sustained virological response.
INTRODUCTION
Hepatitis C is a global health problem, with 170 million
carriers worldwide. The distribution is heterogeneous, with
an estimated 9 million chronic infections in western Eur-
ope and 66–75% of all HCV-infected patients having not
been identiﬁed [1]. The hepatitis C virus (HCV) is a ribo-
nucleic acid (RNA) virus of the family Flaviviridae which
ﬁrst was identiﬁed in 1989 [2,3]. The virus is transmitted
primarily through large or repeated direct exposure to
blood [4].
The HCV infection evolves in different ways for different
patients. The major stepping points in individual histories of
HCV include progression from acute infection to long-term
infection, from long-term disease to cirrhosis, and from cir-
rhosis to decompensation or hepatocellular carcinoma [1,5].
The ﬁrst drug with shown bioactivity against HCV infec-
tion was interferon (IFN) alpha, but with limited effective-
ness: IFN monotherapy results in only 15–20% sustained
response rates [6]. A substantial improvement of response of
approximately twofold over IFN monotherapy was noted
with the combination of IFN and ribavirin (RBV) [7,8]. The
main reason for this still unsatisfactory response to IFN is its
short half-life of approximately 8 h. Thus, in patients treated
with IFN alpha three times weekly, an intermittent increase
in viral load can be observed on treatment-free days [9].
To improve the effectiveness of HCV treatment, a covalent
attachment of a 40-kDa branched-chain polyethylene glycol
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peginterferon (PEG-IFN) alpha-2a, a compound that has
sustained absorption, a slower rate of clearance and a longer
half-life than unmodiﬁed IFN alpha [10,11]. These properties
allow weekly dosing and enhanced clinical efﬁcacy com-
pared with unmodiﬁed IFN [10,12,13]. As with unmodiﬁed
IFN, the combination treatment of PEG-IFN alpha-2a with
RBV enhances efﬁcacy over PEG-IFN alpha-2a monotherapy
[10,14]. The availability of this drug regimen that eradicates
the hepatitis C virus in more than half of the treated patients
provides the medical community with a powerful new
weapon, which is recommended as the standard cure for
HCV infections [15–17].
All patients with long-term hepatitis C are potential can-
didates for antiviral therapy. The risks and beneﬁts of anti-
HCV treatment must be determined for each patient based
on the individual’s disease stage, symptoms, comorbid con-
ditions, risk factors, and the likelihood of adherence and side
effects. For managing side effects, aspects of efﬁcacy and
safety have to be balanced. One of the factors inﬂuencing
safety appears to be the duration of treatment as the time of
exposure to medication. Efﬁcacy results have shown that
treatment duration may be individualized by the HCV
genotype of the patients: whereas patients with HCV geno-
type 1 require treatment for 48 weeks, those with HCV
genotype 2 or 3 seem to be adequately treated in 24 weeks
[18,19].
While the economic aspects of shorter treatment duration
are well accepted, the safety proﬁle of the combination
treatment of PEG-IFN alpha-2a plus RBV over time remains
unclear: What are the consequences not only in clinical
study settings but also in clinical practice? To improve cur-
rent safety and efﬁcacy data and thus provide a better basis
for treatment decisions, this study should evaluate clinical
practice data on HCV treatment with PEG-IFN alpha-2a
(Pegasys
 , Roche Pharma AG, Grenzach-Wyhlen, Germany)
in combination with RBV in patients with chronic hepatitis C
in a setting as close to clinical practice as possible.
METHODS
This data set is based on a German phase III, multi-centre,
open-label study with two treatment groups:
• PEG-IFN alpha-2a in combination with RBV for
24 weeks;
• PEG-IFN alpha-2a in combination with RBV for
48 weeks.
The treatment periods in both groups were followed by an
untreated 24-week follow-up period. The allocation to the
treatment groups was at the discretion of the investigator.
Patients in the 48-week treatment group with detectable
HCV-RNA at week 24 were considered as non-responders
and stopping of treatment was recommended.
The recommended dosage was 180 lg once weekly for
PEG-IFN alpha-2a and 800 mg/day in split doses for RBV.
However, in the meantime the weight-based dosing of RBV
in genotype 1 and 4 patients has been established. Even
though dose adjustment is highly recommended, some
physicians still did stick to their former treatment regimen.
Inclusion criteria were age of at least 18 years, quantiﬁable
HCV-RNA, permanently increased alanine aminotransferase
(ALT)serumlevelsandcompensatedliverdisease.Asustained
virological response (SVR) was deﬁned as non-detectable
HCV-RNA (e.g. <50 IU/mL by the Roche AMPLICOR
 
HCV Test, v2.0; Roche Molecular Systems, Inc., Branchburg,
NJ, USA) 24 weeks after completion of the treatment period.
Statistical analysis
Treatmentassignmenttothetwotreatmentgroupswasatthe
discretion of the physician; therefore, only descriptive statis-
tical methods were used to analyse the results of the study.
In accordance with the intent-to-treat principles, all patients
who received at least one dose of study medication were
included in the analysis of efﬁcacy and safety data. Adverse
events were assigned preferred terms and categorized into
system organ class (SOC) according to MedDRA (Medical
Dictionary for Regulatory Activities; http://www.
meddramsso.com/MSSOWeb/index.htm). Stepwise multiple
logistic regression analysis was used to explore the prognostic
factors for an SVR across both treatment groups. In the step-
wise model-building process, a variable was added to the
model if the adjusted chi-squared statistic was signiﬁcant at
the 0.1 level and a variable was deleted from the model if the
Waldchi-squaredstatisticwasnotsigniﬁcantatthe0.05level.
The following baseline disease and demographic factors were
considered for entry into the model: age, gender (male vs
female), body mass index, body surface area, log10 pre-treat-
ment HCV-RNA titre, baseline ALT quotient, HCV genotype
(1 vs non-1) and histological diagnosis (cirrhotic vs non-
cirrhotic). Furthermore, the assigned treatment duration (24
vs48 weeksoftreatment)wasconsidered.Iftheassumptionof
linearityinthelogitforcontinuousvariableswasnotobvious,
HCV-RNA wasdichotomized usingacutpointof400 000 IU/
mLforall ﬁnalmodels. If theassumption of thelinearity ofthe
logit for continuous variables was violated, appropriate cat-
egories (e.g. high and low virus load) were investigated to
describe the association between the prognostic factor and
SVR (see Fig. 1).
RESULTS
Patients
In all, 320 patients in 35 German centres were screened and
309 patients entered active treatment with PEG-IFN alpha-
2a in combination with RBV:
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• 219 patients for 48 weeks.
Of the patients, 58% were male with mean age of
41.5 years and mean weight of 75.7 kg. In 63% of the pa-
tients, genotype 1 was present and genotype 2 or 3 in 33%
of the patients. In the 24-week treatment group, 93% of the
patients presented with genotype 2 or 3, and in the 48-week
treatment group 86% with genotype 1; 8.2% of the patients
with histological data at baseline (21/309) were suffering
from cirrhosis and details of the Ishak modiﬁed histology
activity index [HAI; 20] showed a mean score of 5.6; 86% of
the patients were treatment-naı ¨ve. The baseline character-
istics of the two combination therapy groups were compar-
able (see Table 1).
Treatment
Duration of treatment
The mean duration of treatment with PEG-IFN alpha-2a was
23.1 weeks in the 24-week group and 41.7 weeks in the
48-week group; 14.4% (13/90) of the patients of the
24-week group and 41.1% (90/219) of the patients of the
48-week group prematurely withdrew from treatment (total:
103/309 patients, 33.3%). As far as the reasons were
known, the most frequent were:
• non-response (10.7%, 33/309);
• adverse event (7.1%, 22/309);
• lost to follow-up (5.5%, 17/309);
• personal reasons (3.6%, 11/309).
The large difference between the two treatment groups is
mainly triggered by the study design, i.e. the longer treat-
ment period and the treatment recommendation to stop
treatment in the 48-week arm, when the HCV-RNA test at
week 24 was positive. During the follow-up period, 15% of
the patients withdrew prematurely (13% in the 48-week
group, 19% in the 24-week group).
Dose
The mean dose of PEG-IFN alpha-2a until termination of
study medication was 178 lg/week in the 24-week group
and 171 lg/week in the 48-week group. The median was
Never received treatment (n=6) Never received treatment (n=2)
Premature termination*(n=90)
Non-Response (n=33)
Patient lost (n=14)
Withdrawn consent (n=2)
Pers. reasons (n=10)
AE (n=19)
Death (n=1)
Other (n=5)
Unknown# (n=24)
Premature termination*(n=13)
Non-Response (n=0)
Patient lost (n=3)
Pers. reasons (n=1)
Inappropriate enrolment (n=1)
AE (n=3)
Other (n=2)
Unknown# (n=5)
Follow-up** completed 
(n=66)
Follow-up** completed
(n=147)
Patients screened (n=317)
48 weeks therapy completed (n=129) 24 weeks therapy completed
(n=77)
Patients treated (n=90) Patients treated (n=219)
PEG/RBV 24 weeks
(n=92)
PEG/RBV 48 weeks
(n=225)
* Multiple reasons possible
** Early withdrawals were followed up for at least 12 weeks, if possible.
# Almost all patients with unknown reason terminated study treatment 1-2 weeks to early.  Fig. 1 Patients ﬂow chart.
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790 Th. Wittho ¨ft et al.180 lg in both groups. For RBV, the mean dose was
796 mg/day in the 24-week group and 780 mg/day in the
48-week group. Treatment was modiﬁed or stopped at least
once in 61.2% (134/219) of the patients of the 48-week
group and in 34.4% (31/90) of the patients of the 24-week
group.
Safety
Adverse events
n all, 97.7% of the patients experienced at least one adverse
event. A majority of these events were treatment-related (in
95.1% of the patients). The most frequently reported adverse
events were those commonly associated with IFN therapy:
headache, inﬂuenza-like illness, fatigue, leucopenia, alope-
cia, nausea and depression (see Table 2). Each of these dis-
orders was reported in more than 22% of the patients. The
incidence of these events was similar in both treatment
groups. There was no speciﬁc organ system showing a
higher incidence of adverse events in both treatment groups.
In the 48-week group, anaemia, cough and bronchitis were
more frequent (22.4%, 9.1% and 7.8%, respectively) than in
the 24-week group (8.9%, 3.3% and 2.2%, respectively). The
incidence rate of adverse events was highest during the ﬁrst
12 weeks of therapy. Thereafter, the number of new onsets
of adverse events decreased rapidly (see Fig. 2). Generally,
the prevalence of adverse events declined rapidly after the
end of treatment.
Psychiatric adverse events
In 146 (47.2%) patients of the overall population (total
251), psychiatric adverse events were reported (47.8% and
47.0% in the 24- and 48-week arms, respectively). Most of
these were depressive events (71 patients, 23.0%) including
depressive disorders and mood alterations with depressive
symptoms. As for the other adverse events, the maximal
incidence of depressive adverse events was during the ﬁrst
12 weeks of treatment.
A majority of the depressive events (72/87) resolved
during the study; 25 of the 72 resolved events were treated
pharmacologically, in most cases with serotonin-reuptake
inhibitors or noradrenalin-reuptake inhibitors. Of the
remaining 15 cases, eight were treated pharmacologically.
Disturbance of sleep was the most frequent psychiatric ad-
verse event next to depression (75 events, of which two were
serious adverse events). The incidence of depression did not
Table 1 Baseline characteristics
PEG-IFN + RBV – 24 weeks
(n ¼ 90)
PEG-IFN + RBV – 48 weeks
(n ¼ 219) Total (n ¼ 309)
Demography
Sex*
Male 59 (65.6) 119 (54.3) 178 (57.6)
Female 31 (34.4) 100 (45.7) 131 (42.4)
Age
 (years) 38.6 ± 10.3 42.7 ± 12.5 41.5 ± 12.1
Weight
 (kg) 77.2 ± 15.4 75.0 ± 13.9 75.7 ± 14.4
BMI
 (kg/m
2) 25.6 ± 4.6 25.2 ± 4.0 25.3 ± 4.2
Virological/biochemical parameters
Genotype*
1 6 (6.7) 188 (86.2) 194 (63.0)
2 14 (15.6) 1 (0.5) 15 (4.9)
3 70 (77.8) 17 (7.8) 87 (28.2)
Other
§ 0 (0.0) 12 (5.5) 13 (3.9)
HCV-RNA
 (10
3IU/mL) 1188 (2–12 300) 1023 (1–33 333) 1071 (1–33 333)
ALT
 (U/L) 73.2 ± 55.6 (n ¼ 89) 56.3 ± 37.5 (n ¼ 216) 61.3 ± 44.1 (n ¼ 305)
Histology n ¼ 75 n ¼ 182 n ¼ 257
Cirrhosis* 7 (9.3) 14 (7.7) 21 (8.2)
Total HAI score
 5.5 ± 3.3 (n ¼ 31) 5.6 ± 3.9 (n ¼ 89) 5.6 ± 3.7 (n ¼ 120)
Mode of HCV infection
Transfusion* 5 (5.6) 40 (18.3) 45 (14.6)
Intravenous drug use* 40 (44.4) 51 (23.3) 91 (29.4)
Percutan./sexual exp.* 4 (4.4) 11 (5.0) 15 (4.9)
Unknown* 35 (38.9) 103 (47.0) 138 (44.7)
Other* 6 (6.7) 14 (6.4) 20 (6.5)
*n (%);
mean ± standard deviation;
mean (min–max).
§In one further patient in the 48-week group genotype was missing.
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PEG-IFN a-2a + ribavirin in clinical practice 791differ in patients with former intravenous drug use compared
with patients who got infected by, e.g. blood transfusion
(data not shown).
Laboratory parameters
With the exception of median ALT and aspartate amino-
transferase (AST) serum levels, which were elevated as
expected in patients suffering from hepatitis C, median serum
levels of all other laboratory parameters were within the
normal range at baseline. Their course during treatment was
comparable in the treatment groups.
Median values of white blood count and platelets as well
as median haemoglobin concentration decreased in all
groups during treatment and returned to baseline after
treatment. Median ALT and AST levels decreased during
treatment and were within the normal range or slightly
above at the end of treatment. The median decrease was
slightly more pronounced in the 24-week group, reﬂecting
the better therapeutic response of patients, with genotype 2
or 3 being the majority in this group.
Serious adverse events
Nine per cent of the patients experienced at least one serious
adverse event (SAE). The proportion of patients with at least
one SAE was higher in the PEG-IFN plus RBV 48-week group
(10.5%) than in the PEG-IFN plus RBV 24-week group
(4.4%). The most frequent SAEs were psychiatric disorders
(2.3%), infections (1.9%), and cardiac and gastrointestinal
disorders (1.6%).
Drug-related SAEs were reported in 5.5% of the patients.
Most frequent were psychiatric disorders being reported in
more than 2% of the patients in both treatment groups and
being the only drug-related serious adverse event in the 24-
week group. In the 48-week group, only gastrointestinal,
immune system, cardiac, endocrine and hepatobiliary dis-
orders were reported in more than one patient.
Deaths
Two patients died during the follow-up period: one patient
of the PEG-IFN plus RBV 24-week group who suffered from
psychotic disorder committed suicide 19 months post-
treatment. One patient of the PEG-IFN plus RBV 48-week
Table 2 Common adverse events (‡10%
of patients) during treatment and follow-
up period Adverse event
PEG-IFN + RBV –
24 weeks (n ¼ 90)
PEG-IFN + RBV –
48 weeks (n ¼ 219)
Total
(n ¼ 309)
Headache 38 (42.2) 82 (37.4) 120 (38.8)
Inﬂuenza like illness 30 (33.3) 72 (32.9) 102 (33.0)
Fatigue 26 (28.9) 55 (25.1) 81 (26.2)
Leucopenia 18 (20.0) 60 (27.4) 78 (25.2)
Alopecia 14 (15.6) 57 (26.0) 71 (23.0)
Depression 19 (21.1) 52 (23.7) 71 (23.0)
Nausea 17 (18.9) 52 (23.7) 69 (22.3)
Anemia 8 (8.9) 49 (22.4) 57 (18.4)
Pyrexia 17 (18.9) 36 (16.4) 53 (17.2)
Thrombocytopenia 11 (12.2) 42 (19.2) 53 (17.2)
Pruritus 12 (13.3) 39 (17.8) 51 (16.5)
Weight decreased 12 (13.3) 39 (17.8) 51 (16.5)
Diarrhoea 13 (14.4) 35 (16.0) 48 (15.5)
Inﬂuenza 13 (14.4) 30 (13.7) 43 (13.9)
Arthralgia 8 (8.9) 33 (15.1) 41 (13.3)
Myalgia 11 (12.2) 29 (13.2) 40 (12.9)
Insomnia 8 (8.9) 31 (14.2) 39 (12.6)
Asthenia 10 (11.1) 22 (10.0) 32 (10.4)
Values given in parentheses are percentages.
Study weeks
0
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Fig. 2 Incidence of adverse events during treatment and
follow-up phase.
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792 Th. Wittho ¨ft et al.group, who was prematurely withdrawn because of leu-
copenia, thrombopenia, elevated ALT levels and signs of
cholestasis, developed sepsis and died during the follow-up
period.
Efﬁcacy
An SVR was achieved in 151 of the 309 patients (48.9%).
The SVR rate was 64.4% (58/90 patients) in the PEG-IFN
plus RBV 24-week group and 42.5% (93/219 patients) in
the PEG-IFN plus RBV 48-week group.
Considering treatment history, there is no difference in
response between patients whose HCV infection was never
treated before and patients who had been previously treated
without sustained success. Response rates were alike in
treatment-naı ¨ve patients and in relapsers to previous IFN
treatment. No signiﬁcant difference has been observed in
non-cirrhotic and cirrhotic patients with regard to the SVR
rates. However, only 21 patients did present F4 ﬁbrosis at
baseline.
The baseline viral load data show relevant differences only
in the 48-week treatment group, which is mainly composed
of HCV genotype 1 patients. In these patients, a low viral
load appears to correspond to an increased probability of
achieve an SVR (see Table 3). There was no marked differ-
ence in response rates when stratifying for gender, weight
and body mass index.
In patients with genotype 2 or 3, a longer duration of
treatment (48 vs 24 weeks) did not result in any additional
beneﬁt. In patients with genotype 1, the SVR was higher
in patients being treated for 48 weeks (40% vs 17%; see
Table 4 and Fig. 3).
Multiple logistic regression
Three independent factors predictive for increased SVR were
identiﬁed using multiple logistic regression analysis: geno-
type non-1 (P ¼ 0.003), a pre-treatment HCV-
Table 3 Sustained virological response by treatment group
PEG-IFN + RBV – 24 weeks
(n ¼ 90), n (%)
PEG-IFN + RBV – 48 weeks
(n ¼ 219), n (%)
Total (n ¼ 309),
n (%)
All patients 58 (64.4) 93 (42.5) 151 (48.9)
Treatment status at baseline
Treatment-naı ¨ve 52/80 (65.0) 78/184 (42.4) 130/264 (49.3)
Relapser 6/10 (60.0) 15/33 (45.5) 21/43 (48.8)
Baseline viral load (IU/mL)
0–400 000 29/38 (76.3) 49/87 (56.3) 78/125 (62.4)
>400 000 29/52 (55.8) 44/132 (33.3) 73/184 (39.7)
0–800 000 35/55 (63.6) 71/151 (47.0) 106/206 (51.5)
>800 000 23/35 (65.7) 22/68 (32.4) 45/103 (43.7)
Table 4 Sustained virological response by genotype
Genotype 1, SVR Genotype 2 or 3, SVR Other genotypes, SVR
n % n % n %
PEG-IFN + RBV – 24 weeks 1/6 16.7 57/84 67.9 0
PEG-IFN + RBV – 48 weeks 75/188 39.9 10/18 55.6 7/12 58.3
Total 76/194 39.2 67/102 65.7 7/12 58.3
0
10
20
30
40
50
60
70
PEG-IFN +
RBV 24
weeks
PEG-IFN +
RBV 48
weeks
Total
Patients with HCV GT 1
Patients with HCV GT 2 and 3
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Fig. 3 Sustained virological response (SVR) and HCV
genotype.
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PEG-IFN a-2a + ribavirin in clinical practice 793RNA £ 400 000 IU/mL (P ¼ 0.002) and lower age (P ¼
0,0053). All other baseline factors and the intended treat-
ment duration did not enter the ﬁnal model.
The odds for SVR was about 2.5 times higher for genotype
non-1 compared with those patients with genotype 1 and for
patients with HCV-RNA £ 400 000 IU/mL compared with
those patients with HCV-RNA ‡ 400,000 IU/mL. The odd
for SVR was increased by a factor of 1.35 for patients who
are 10 years younger than their counterparts.
DISCUSSION
The aim of this study was to evaluate the safety and efﬁcacy
of PEG-IFN alpha-2a in a setting as close to everyday clinical
practice as possible. Therefore, the design of the study was as
realistic as possible: Patients were not randomized but as-
signed to one of the treatment groups at the investigator’s
discretion reﬂecting everyday clinical practice according to
current guidelines. Participating centres were hospitals and
ofﬁce-based physicians who were regularly involved in the
care of chronic hepatitis C patients, but did not have had any
experience with PEG-IFN alpha-2a.
Eventhough the number of recruiting centres seems to be
high, this refers to the rising number of physicians taking
care of HCV patients after PEG-IFN has been introduced to
the German market and became standard of care quite
rapidly. Even in large international multi-centre trials (e.g.
phase II and III) the numbers of investigational sites are high
while the number of recruited patients per site is low.
Therefore, our collected data did not account for homogen-
ous distribution, as in well-balanced randomized studies,
either with regard to patients or to physicians or to treat-
ment modalities.
The treatment groups included PEG-IFN alpha-2a (Pega-
sys
 ) in combination with RBV for 24 or 48 weeks. Most of
the patients (70.9%, 219/309) were assigned to the 48-
week combination group. According to recommentations, a
reduction of treatment duration was intended for patients
with genotype non-1. This was true for 29.1% (90/309) of
the patients being assigned to the 24-week combination
group and as expected, 93% of these patients presented with
genotype 2 or 3, whereas patients with genotype 1 were
mostly in the 48-week treatment group (86%).
The clinical practice data of the current study revealed no
surprises in safety results. No unexpected safety concerns
were observed. The safety proﬁle of the treatment with PEG-
IFN alpha-2a (Pegasys
 ) plus RBV was in accordance with
the safety proﬁle known from previous studies [10,13,14].
The incidence of depression was reported to be highest
during the ﬁrst 12 weeks of treatment. This might be due to
an increased awareness of the incidence of depressive
symptoms being known from previous studies. As expected,
safety concerns present as a problem for almost all patients
with no organ class, demonstrating a clearly increased
incidence in one of the groups. However, most of the prob-
lems appear in the initial weeks of treatment. They appear to
be manageable because the rate of therapy withdrawals due
to adverse events of 7.1% of all patients is relatively low. This
rate corresponds to the rate found by Fried et al. [14] – 3%
for laboratory abnormalities and 7% for other adverse
events. However, a successful treatment needs an active
handling of tolerability problems. This means a close contact
with the patients and development of individual strategies to
overcome possible adverse events particularly in the initials
weeks of treatment.
As expected, treatment with PEG-IFN alpha-2a (Pega-
sys
 ) plus RBV for 24 weeks was better tolerated than for
48 weeks. The incidence of serious adverse events was
distinctly lower in the 24-week group (4.4% vs 10.5%) as
well as the incidence of dose reductions and withdrawals.
These results are in accordance with studies comparing 24
and 48 weeks of treatment. So, Hadziyannis et al. [19]
reported incidence rates of serious adverse events of 3–7%
for the 24-week groups and 9–10% for the 48-week
groups. Individual adverse events were equally frequent in
both the 24- and 48-week group, with the exception of
anaemia, cough and bronchitis being more frequent in the
48 week group.
An SVR was achieved in 48.9% of the patients. General
SVR rates depend on the composition of population. Thus, it
makes more sense to stratify the SVR rates for HCV geno-
type: for patients with genotype 2 or 3 an SVR rate of 65.7%
was documented. For genotype 2 or 3 patients, being treated
according to recommendations for 24 weeks, the SVR was
67.9%. Patients with genotype 1 achieved an SVR of 39.1%,
whereas genotype 1 patients with a 48-week combination
treatment achieved an SVR of 39.9%. Compared with pre-
vious study results, the current SVR rates are slightly lower:
Bacon [21] reports SVR rates between 54% and 61% for all
patients and SVR rates between 42% and 48% for genotype
1 patients. The reason for the slightly reduced SVR rates in
this study may be associated with the open practice char-
acter of the study. As per deﬁnition, the calculation of SVR
rates includes patients with missing HCV-RNA post-treat-
ment values as non-responders. As this study includes a rate
of 26% of these patients, looking at the SVR rates might
possibly give the wrong picture of the real effect of the study
medication more than in pivotal trials, in which patients
may be easier available for follow-up visits.
Of great interest for the prognosis of treatment success are
baseline characteristics of the patients which may corres-
pond to the efﬁcacy of treatment. As explained, one of these
criteria is the HCV genotype of the patients. On top of this,
the viral load at baseline is discussed as an important
parameter [22]. Current results conﬁrm this fact for the 48-
week treatment group being dominated by genotype 1 pa-
tients. In this group, a low viral load (up to 400 000 IU/mL)
is associated with a higher SVR rate (56.3%), whereas the
SVR for patients with a high viral load (>400 000 IU/mL)
was 33.3%. Data presented at the last AASLD in Boston by
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ings that, choosing a lower viral cut-off of 400 000 IU/mL
prior to treatment is a signiﬁcant predictive marker for SVR
in patients with genotype 1. For the 24-week treatment
group being dominated by genotype 2 and 3 patients, there
was no relevant difference between patients with low and
high viral loads. This result is in line with data shown by
Hadziyannis et al. [19] and Fried et al. [25].
The well-known insufﬁcient response rates of interferon
monotherapy or combination therapy lead to the important
question if patients without sustained response after IFN
pretreatment will also show a higher rate of non-response to
following PEG-IFN treatment. According to the results pre-
sented in Refs [18,26], reduced response rates for patients
who failed to respond to a previous antiviral treatment are
expected. However, the results of the current data set –
including 43 IFN pretreatments out of 309 patients show the
contrary results: 21 of the 43 pretreated patients (48.8%)
achieved an SVR compared with 48.9% in the total popu-
lation. Thus, for patients without sustained response after
IFN standard therapy, treatment with PEG-IFN may be a
promising treatment option. As far as our results have
shown, their chance to respond to treatment is similar to
treatment-naı ¨ve patients.
In summary, the results of the current study have shown
that the well-known risk–beneﬁt ratio of the treatment of
chronic hepatitis C with PEG-IFN alpha-2a (Pegasys
 ) plus
RBV found in clinical trial settings could also be conﬁrmed in
a clinical practice setting. The safety proﬁle is similar and
shows the highest incidence of adverse events in the ﬁrst
12 weeks of treatment. Although almost all patients (95%)
were affected by drug-related adverse events, these were
manageable in most cases: Only in 7.1% of the patients was
treatment terminated prematurely because of adverse events.
As recommended, the duration of treatment was adapted to
HCV genotype in most cases: patients with genotype 2 or 3
were treated for 24 weeks and patients with genotype 1 for
48 weeks. As expected, patients with genotype 2 or 3 being
treated for 48 weeks did not beneﬁt from the prolonged
treatment. Replicating the results of clinical trials in a clinical
practice setting, the recommended therapy regimens for
these two populations were highly efﬁcacious in daily routine
practice and conﬁrm the reasonable risk–beneﬁt ratio for the
treatment with PEG-IFN alpha-2a plus RBV.
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